© 2022 MJH Life Sciences™ and Contemporary OB/GYN. All rights reserved.
Vulvovaginal Candidiasis
The Challenges of Diagnosing Recurrent Vulvovaginal Candidiasis
November 21, 2022
Michael L. Krychman, MD, and Jack D. Sobel, MD, review diagnostic criteria of diagnosis of RVVC and the impact of misdiagnosis.
Pathophysiology and Impact of Vulvovaginal Candidiasis
November 21, 2022
Michael L. Krychman, MD and Jack D. Sobel, MD, talk about the signs and symptoms of vulvovaginal candidiasis as well as its effect on patient quality of life.
Bacterial vaginosis during pregnancy may heighten risk of preterm birth, pregnancy loss
November 21, 2022
Bacterial vaginosis during pregnancy may lead to increased risks for preterm birth, preterm delivery, and spontaneous abortion, according to new research in the Archives of Gynecology and Obstetrics.
Dare Bioscience announces grant to develop vaginal thermosetting gel for delivery of live biotherapeutics
November 16, 2022
Daré Bioscience announced yesterday that it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to support its efforts related to the development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.
Efficacy of N. sativa-honey vs. clotrimazole for VVC
November 09, 2022
A study published in the journal Evidence-Based Complementary and Alternative Medicine found that both Nigella sativa (N. sativa) (black seed and black cumin)-honey vaginal cream and the antifungal medication clotrimazole significantly improve the symptoms of vulvovaginal candidiasis (VVC).
Can intimate hygiene practices help manage vulvovaginal candidiasis?
October 18, 2022
A research study examined the role of a medicated feminine wash as an adjunct treatment for candidiasis.
Prevalence of Candida species with IUD placement
October 18, 2022
Three months after copper intrauterine device (IUD) insertion, nearly 1/3 of women were diagnosed with vulvovaginal candidiasis, compared to nearly 25% of women who received a hormonal IUD, according to a prospective study published in the journal Cellular and Molecular Biology.
VVC in pregnancy
October 11, 2022
The risk of vulvovaginal candidiasis (VVC) during pregnancy tends to peak in the third trimester, according to a review published in Infectious Diseases in Obstetrics and Gynecology. Risk factors range from contraceptive and antibiotic use to patients’ hygiene and overall health.1 With data regarding VVC and pregnancy incomplete and often conflicting, review authors say, more research is needed.
Phase 3 data show oral oteseconazole successful for treating vulvovaginal candidiasis and infections
September 21, 2022
The medication also performed comparably to vulvovaginal candidiasis (VVC) standard-of-care fluconazole for treating acute VVC infection.
Host immune responses in recurrent vulvovaginal candidiasis
September 15, 2022
A study published in Frontiers in Immunology indicates that for the prognosis of recurrent vulvovaginal candidiasis (RVVC) and vulvovaginal candidiasis (VVC), the host-immune responses, particularly Th1/2 immunity, may play a vital role.